Colorectal Cancer New Reference: Encorafenib, Cetuximab with FOLFOX for bRAF Mutated Metastatic Colorectal Cancer Ulas D. Bayraktar, MD 2025-06-02
Breast Cancer New Protocol: Neoadj Pembrolizumab + TP for her2+ Breast Cancer Ulas D. Bayraktar, MD 2025-05-05
Colorectal Cancer New Reference: Neoadjuvant FOLFOX + Panitumumab for Colon Cancer Ulas D. Bayraktar, MD 2025-05-05
Follicular Lymphoma New Reference: RiTUXimab alone for Follicular Lymphoma Ulas D. Bayraktar, MD 2025-05-05
GastroEsophageal Cancer New Protocol: TFOX for Advanced Gastric Cancer Ulas D. Bayraktar, MD 2025-05-05
Non-Small Cell Lung Cancer New Reference: Zongertinib for her2 Mutated NSCLC Ulas D. Bayraktar, MD 2025-05-05
Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
Mantle cell lymphoma New Reference: Acalabrutinib with R-Bendamustine in Untreated Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2025-05-04
GastroEsophageal Cancer New Protocol: Atezolizumab and Trastuzumab with CapeOx for Periop Her2+ Gastric Cancer Ulas D. Bayraktar, MD 2025-05-04
Mesothelioma New Protocol: Atezolizumab with Carbo-Pem-Bev for Pleural Mesothelioma Ulas D. Bayraktar, MD 2025-05-04
